Dyne Therapeutics (DYN) – Analysts’ Recent Ratings Changes

Dyne Therapeutics (NASDAQ: DYN) has recently received a number of price target changes and ratings updates:

• 3/21/2025 – Dyne Therapeutics had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a “neutral” rating on the stock.
• 3/17/2025 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
• 3/17/2025 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock.
• 3/12/2025 – Dyne Therapeutics is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $50.00 price target on the stock.
• 3/7/2025 – Dyne Therapeutics is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $50.00 price target on the stock.
• 2/28/2025 – Dyne Therapeutics had its price target lowered by analysts at Piper Sandler from $53.00 to $48.00. They now have an “overweight” rating on the stock.
• 2/28/2025 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock.
• 2/28/2025 – Dyne Therapeutics had its price target lowered by analysts at HC Wainwright from $55.00 to $46.00. They now have a “buy” rating on the stock.

Dyne Therapeutics Trading Down 8.8 %

Shares of NASDAQ DYN traded down $1.01 during trading hours on Monday, reaching $10.44. The stock had a trading volume of 1,275,931 shares, compared to its average volume of 1,375,314. The business’s fifty day moving average price is $13.27 and its two-hundred day moving average price is $23.39. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -2.93 and a beta of 1.11. Dyne Therapeutics, Inc. has a 52-week low of $9.97 and a 52-week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04. Equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 6,237 shares of company stock worth $77,760. Insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of DYN. Quantbot Technologies LP acquired a new position in shares of Dyne Therapeutics in the 3rd quarter valued at $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics during the 3rd quarter worth approximately $36,000. GF Fund Management CO. LTD. acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at $50,000. KBC Group NV boosted its holdings in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after buying an additional 978 shares in the last quarter. Finally, Summit Investment Advisors Inc. grew its position in Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock valued at $203,000 after buying an additional 721 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.